BACKGROUND: There is limited information on actions taken in response to drug safety signals originating from a spontaneous reporting system (SRS) in pharmacovigilance. In The Netherlands the Pharmacovigilance Centre Lareb is an independent organization that works in close collaboration with the Dutch regulatory agency, the Medicines Evaluation Board (MEB).
OBJECTIVE: The objective of this study is to gain insight in steps undertaken on signals originating from the SRS and disseminated by Lareb from 2008–2012.
METHOD: For all signals the recommendations of Lareb and the following steps proposed by the MEB were analyzed. Secondary outcomes were prioritization of the signal, the year of dissemination and if Lareb published (inter)nationally about the signal. Pearson’s Chi-square (X2) and Mantel-Haenszel statistics were used for statistical analysis.
RESULTS: Of all signals disseminated by Lareb from 2008–2012, 90,7% resulted in an action: in 87% a regulatory action and in 36% an (inter)national publication. Generally, Lareb’s recommendations correspond to steps undertaken by the MEB.
CONCLUSION: This study found influence of signal prioritization on Lareb’s recommendations but not on the steps undertaken by the MEB. Trends over time were only seen for steps undertaken by the MEB. These differences are most probably due to responsibilities of the different EU member states of various drugs.
World Health Organization. The importance of pharmacovigilance: Safety monotoring of medicinal products. 2002.
2.
LasserKEAllenPDWoolhandlerSJHimmelsteinDUWolfeSMBorDH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287(17):2215–20.
3.
van PuijenbroekEDiemontWLvan GrootheestK. Application of Quantitative Signal Detection in the Dutch Spontaneous Reporting System for Adverse Drug Reactions. Drug Saf. 2003;26(5):293–301.
4.
European Medicines Agency and Heads of Medicines Agencies. Guideline on good pharmacovigilance practices (GVP), Annex I, Definitions. 2012. P 19. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500143294.pdf
5.
WallerPCLeeEH. Responding to drug safety issues. Pharmacoepidemiol. Drug Saf. 1999;8(7):535–52.
6.
van HunselFHärmarkLPalS, et al. Experiences with Adverse Drug Reaction Reporting by Patients; An 11-Country Survey. Drug Saf. 2012;35(1):45–60.
7.
van PuijenbroekEPvanGKDiemontWLLeufkensHGEgbertsAC. Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. Br J Clin Pharmacol. 2001;52(5):579–86.
8.
http://www.cbg-meb.nl/CBG/en/about/organisation/default.htm. Medicine Evaluation Board. 2014.
9.
EbbersHCMantel-TeeuwisseAKSayed-TabatabaeiFAMoorsEHSchellekensHLeufkensHG. The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals. Eur J Clin Pharmacol. 2013;69(2):217–26.
10.
Netherlands Pharmacovigilance Centre Lareb. Quarterly report 2012-3, Overview on generated pharmacovigilance signals and the actions of Lareb and the MEB. 2012; pp 30.
11.
The EU Pharmacogivilance system [online]. (version date: 2012, access date: 12-6-2012) The European Commission (EM).
12.
BroekmansAWMolPG. The new pharmacovigilance legislation in practice. Ned Tijdschr Geneeskd. 2014;158:A7129. http://www.ncbi.nlm.nih.gov/pubmed/24846112.
PacurariuACColomaPMvanHAGenovGSturkenboomMCStrausSM. A Description of Signals During the First 18 Months of the EMA Pharmacovigilance Risk Assessment Committee. Drug Saf. 2014;37(12):1059–66.
15.
SeabrokeSWiseLWallerP. Development of a novel regulatory pharmacovigilance prioritisation system: An evaluation of its performance at the UK Medicines and Healthcare products Regulatory Agency. Drug Saf. 2013;36(10):1025–32.
PassierJLMvan PuijenbroekEPvan GrootheestAC. Pancreatitis Associated with the Use of Itraconazole. Drug Saf. 2009;32(10):893.
18.
PassierJLvan PuijenbroekEPJonkersGJvan GrootheestAC. Pancreatitis associated with the use of itraconazole. Neth J Med. 2010;68(6):285–9.
19.
Netherlands Pharmacovigilance Centre. Sexual dysfunction associated with the use of SSRIs (article in Dutch). GeBu 1999.
20.
EkhartGCvan PuijenbroekEJ. Does sexual dysfunction persist upon discontinuation of selective serotonin reuptake inhibitors? (Article in Dutch). Journal of Psychiatry. 2014;56(5):336–40.
21.
BorgsteedeSBruggemanRHoefnagelRHuiskesMvanPE. Tamsulosin and hyperglycaemia in patients with diabetes. Neth J Med. 2010;68(3):141–3.
22.
Netherlands Pharmacovigilance Centre. Metronidazole and peripheral oedema (articel in Dutch). GeBu. 2013;5(57):58.
23.
Pharmacovigilance Risk Assessment Commitee (PRAC). Minutes of the meeting of 8-11 September 2014. 2014; p.15 http://www.google.nl/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0CCEQFjAA&url=http%3A%2F%2Fwww.ema.europa.eu%2Fdocs%2Fen GB%2Fdocument_library%2FMinutes%2F2014%2F10%2FWC500175797.pdf&ei=fSnSVKeGAcXfaqC3gIAL&usg=AFQjCNHdZpZTNqrRilq2qzTLOSjsbdi61g
24.
Netherlands Pharmacovigilance Centre Lareb. SSRIs and hypoglycemia in patient with diabetes mellitus (article in Dutch). Dutch Drug Bulleting. 20201;44:67–8.
25.
SchollJHvan PuijenbroekEP. Hearing impairment associated with oral terbinafine use: A case series and case/non-case analysis in the Netherlands Pharmacovigilance Centre Lareb database and VigiBase. Drug Saf. 2012;35(8):685–91.
26.
RolfesLKolfschotenJvan HunselFvan PuijenbroekEvan GrootheestK. Validation of Signal Impact assessment Tool in Order to Explore Pharmacovigilance Signals’ Follow-Up Actions. Pharmacoepidemiol Drug Saf. 2014;23(S1):39.
